Effectiveness and safety over 3 years after the 2-year U-Act-Early trial of the strategies initiating tocilizumab and/or methotrexate.
Verhoeven MMA, Tekstra J, Welsing PMJ, Pethö-Schramm A, Borm MEA, Bruyn GAW, Bos R, Griep EN, Klaasen R, van Laar JM, Lafeber FPJG, Bijlsma JWJ, de Hair MJH, Jacobs JWG.
Verhoeven MMA, et al. Among authors: de hair mjh.
Rheumatology (Oxford). 2020 Sep 1;59(9):2325-2333. doi: 10.1093/rheumatology/kez602.
Rheumatology (Oxford). 2020.
PMID: 31859346
Free PMC article.
Clinical Trial.